Vtesse, Inc., a company committed to developing medicines to benefit patients with ultra rare, life-threatening diseases, announced today the appointment of Jason Meyenburg as Chief Commercial Officer. Mr. Meyenburg joins the company from Alexion Pharmaceuticals, Inc., where he most recently served as Senior Vice President, Commercial Operations, The Americas.
“As we near completion of enrollment in our pivotal Phase 2b/3 clinical trial of our lead drug candidate, VTS-270, our primary goal is to advance regulatory submissions. Assuming we receive favorable responses from U.S. and European regulatory agencies, our next goal will be to rapidly provide access to VTS-270 for the children suffering from NPC and its debilitating symptoms,” said Ben Machielse, Drs., President and Chief Executive Officer of Vtesse, Inc. “As someone with deep experience supporting the roll out of rare disease medicines, Jason has the know-how, passion and dedication required to help us to quickly make VTS-270 available for patients in need, pending regulatory approvals.”